A groundbreaking device designed to restore lymphatic flow in patients with acute decompensated heart failure (ADHF) is moving towards larger clinical trials, despite a recent patient death and a serious adverse event observed during a feasibility study. WhiteSwell’s eLym system has demonstrated significant positive outcomes in reducing congestion and promoting fluid loss in a preliminary trial, fueling optimism for its potential to revolutionize ADHF treatment.
Main Facts:
WhiteSwell is forging ahead with plans for a randomized clinical trial, dubbed LYMPH-HF, to evaluate its eLym system for treating acute decompensated heart failure (ADHF). This decision follows promising preliminary efficacy data from the ongoing single-arm DELTA-HF feasibility study, which enrolled 40 adults with ADHF who had previously shown an insufficient response to standard diuretic therapies and presented with multiple comorbidities.
The DELTA-HF study revealed compelling results at the six-month follow-up mark: 82.5% of patients remained free from heart failure-related hospitalizations, and the eLym system successfully lowered thoracic duct pressure in an impressive 98% of participants. Furthermore, the treatment cohort achieved a median modified EVEREST clinical congestion score of 0, indicating a significant reduction in fluid overload. Patients also experienced an average weight loss of 6.8kg (15 lbs) within the six-month period.
However, the study was not without its challenges. A treatment-related serious adverse event resulted in the death of one patient, attributed to a vascular complication during the access procedure prior to the insertion of the investigational device. Another patient experienced a severe episode of hypotension, which was successfully managed. These events have prompted WhiteSwell to implement enhanced safety protocols and training for future trials.
Chronology of Developments:
The journey of the eLym system from concept to potential clinical implementation has been marked by incremental progress and rigorous evaluation.
-
Feasibility Study (DELTA-HF): WhiteSwell initiated the DELTA-HF trial (NCT05747196) as a single-arm feasibility study to assess the eLym system in patients with ADHF. This study involved 40 adults with a history of diuretic resistance and multiple comorbidities. The primary objective was to gather preliminary data on the system’s safety and efficacy in restoring lymphatic flow and alleviating congestion.
-
Presentation of Preliminary Data: The encouraging interim results from the DELTA-HF trial were presented at the 2026 Heart Failure Congress, organized by the European Society of Cardiology’s (ESC) Heart Failure Association, held in Barcelona from May 9th to 12th. This presentation offered the medical community its first in-depth look at the system’s performance.
-
Patient Death and Serious Adverse Event: During the course of the DELTA-HF study, a critical event occurred: one patient experienced a procedure-related serious adverse event that led to death. Investigations revealed a vascular complication during the access procedure. Additionally, another patient suffered from a severe case of low blood pressure, which was resolved with treatment.
-
Company Response and Mitigation Strategies: In response to these serious events, WhiteSwell has undertaken thorough investigations and enhanced its training protocols for medical staff involved in the procedure. The company emphasized that the vascular complication occurred prior to the introduction of the investigational device itself.
-
Planning for Randomized Trial (LYMPH-HF): Despite the setbacks, WhiteSwell has reaffirmed its commitment to advancing the eLym system. The company is now actively planning to launch the randomized LYMPH-HF trial later in 2026. This pivotal trial is designed to rigorously evaluate the therapy’s benefit-risk profile in a larger and more diverse ADHF patient population.
-
Geographic Expansion of Future Trials: The upcoming LYMPH-HF trial is slated to be conducted across multiple international sites, including the United States, Europe, Canada, and Israel, reflecting a global approach to validating the eLym system.
Supporting Data and Efficacy of the eLym System:
The eLym system represents a novel therapeutic approach to ADHF, targeting the underlying lymphatic dysfunction that contributes to fluid overload. The device is designed to work in conjunction with standard diuretic therapies, aiming to enhance their effectiveness by optimizing lymphatic drainage.
-
Mechanism of Action: The eLym system functions by creating a localized region of low pressure within the thoracic duct, a crucial component of the body’s lymphatic system responsible for draining fluid from the chest. This pressure gradient facilitates the unimpeded flow of lymph fluid, allowing for more efficient removal of excess interstitial fluid that accumulates in patients with ADHF. By restoring proper lymphatic flow, the system aims to reduce venous congestion and improve cardiac function.
-
Key Efficacy Endpoints in DELTA-HF: The preliminary data from the DELTA-HF trial provided compelling evidence of the eLym system’s potential efficacy:
- Reduced Hospitalizations: A significant 82.5% of patients treated with the eLym system remained free from heart failure-prompted hospitalizations six months post-treatment. This outcome is particularly noteworthy given that participants in the study had a history of insufficient response to diuretics, suggesting the eLym system can offer a valuable therapeutic adjunct.
- Lowered Thoracic Duct Pressure: The system demonstrated a remarkable success rate in lowering thoracic duct pressure, achieving this in 98% of treated patients. This directly reflects the system’s ability to effectively influence lymphatic flow.
- Alleviation of Congestion: The median modified EVEREST clinical congestion score for the treatment cohort reached 0 at six months. The EVEREST score is a critical measure of fluid overload in heart failure patients, and a score of 0 signifies the absence of significant congestion. This indicates a substantial improvement in the patients’ fluid balance and overall clinical status.
- Significant Weight Loss: Patients in the eLym treatment group experienced an average weight loss of 6.8kg (approximately 15 lbs) by the six-month mark. This substantial reduction in body weight is a strong indicator of fluid mobilization and effective management of edema, a hallmark symptom of ADHF.
-
Long-Term Data: The presented data covered a six-month follow-up period, providing insights into the sustained benefits of the eLym system. The positive outcomes observed at this extended timeframe suggest that the therapeutic effects are not merely transient.
Official Responses and Safety Concerns:
The emergence of a patient death and a serious adverse event in a clinical trial naturally raises questions and necessitates a transparent and robust response from the investigating company. WhiteSwell has addressed these concerns directly, emphasizing their commitment to patient safety and the rigorous investigation of these events.
-
Statement from Sergio Shkurovich, VP Clinical Affairs, WhiteSwell: In a direct communication with Clinical Trials Arena, Sergio Shkurovich provided crucial details regarding the patient death. He stated: "As disclosed in the DELTA-HF results, one patient experienced a procedure-related serious adverse event that resulted in death. In this case, a vascular complication occurred during the access procedure prior to introduction of the investigational device. The company took this event very seriously and performed a thorough investigation and has supplemented training to mitigate risk."
-
Nature of the Adverse Events:
- Fatal Complication: The fatal event was attributed to a vascular complication that occurred during the initial access procedure, before the eLym device was deployed. Specifically, the patient suffered a hematoma within the mediastinum, the anatomical space located in the chest between the lungs, which houses vital organs such as the heart and esophagus. This highlights the inherent risks associated with invasive vascular access procedures.
- Hypotension: Another patient experienced a serious case of low blood pressure (hypotension). Fortunately, this adverse event was resolved with appropriate medical intervention and treatment.
-
Mitigation Strategies for Future Trials: WhiteSwell has outlined a comprehensive strategy to address and mitigate potential risks in the upcoming LYMPH-HF trial:
- Enhanced Training: The company has reinforced and supplemented training for all personnel involved in the procedure, focusing on best practices for vascular access and complication management.
- Independent Safety Oversight: A key element of their safety plan involves robust independent safety oversight. This typically includes a Data Safety Monitoring Board (DSMB) composed of independent medical experts who regularly review trial data and patient safety.
- Rigorous Monitoring: The trial protocol will incorporate rigorous and continuous monitoring of patients for any signs of adverse events.
- Predefined Safety Endpoints: Specific safety endpoints will be clearly defined in the trial protocol, allowing for systematic evaluation and early detection of any emerging safety concerns.
- Ongoing Reviews: Regular reviews by investigators and regulatory authorities will be conducted throughout the trial to ensure adherence to safety protocols and to address any unforeseen issues promptly.
-
Commitment to Randomized Controlled Trial: Shkurovich emphasized the company’s belief in the scientific imperative of a randomized controlled trial: "WhiteSwell and the oversight committee agree that conducting a randomized controlled trial is the appropriate next step to fully evaluate the therapy’s benefit-risk profile in patients with ADHF." This sentiment underscores the understanding that while the feasibility study provided valuable insights, a randomized controlled trial is essential for establishing definitive evidence of efficacy and safety compared to current standards of care.
Implications and Future Outlook:
The development of the eLym system and its progression through clinical trials carries significant implications for the management of ADHF, a condition characterized by high morbidity, mortality, and substantial healthcare costs.
-
Addressing an Unmet Need: Acute decompensated heart failure remains a leading cause of hospitalization and a major public health challenge globally. Patients with ADHF often experience severe symptoms of fluid overload, including shortness of breath, edema, and fatigue, leading to frequent hospital readmissions and a diminished quality of life. Current treatment strategies, primarily relying on diuretics, are not always sufficient, particularly in patients with diuretic resistance. The eLym system offers a novel approach that directly addresses the underlying lymphatic dysfunction contributing to congestion, potentially filling a critical unmet need in ADHF therapy.
-
Potential to Reduce Hospitalizations and Re-admissions: The promising data from the DELTA-HF trial, particularly the reduction in heart failure-prompted hospitalizations, suggests that the eLym system could play a crucial role in reducing the burden of ADHF on patients and healthcare systems. Lowering re-admission rates is a key objective in heart failure management, as repeated hospitalizations are associated with increased mortality and decreased functional capacity.
-
Transforming ADHF Treatment Paradigms: If the LYMPH-HF trial confirms the efficacy and safety of the eLym system, it could usher in a new era of ADHF treatment. By integrating lymphatic support into the therapeutic armamentarium, clinicians might be able to achieve more comprehensive and sustained relief for patients, moving beyond solely focusing on diuretic management. This could lead to improved patient outcomes, enhanced quality of life, and potentially reduced long-term healthcare expenditures.
-
The Importance of Balancing Innovation with Safety: The events in the DELTA-HF trial serve as a stark reminder of the inherent risks associated with developing novel medical interventions. While the pursuit of innovative treatments is essential for advancing healthcare, it must be balanced with an unwavering commitment to patient safety. WhiteSwell’s transparent reporting and proactive implementation of enhanced safety measures are crucial steps in navigating this delicate balance. The thorough investigation and subsequent adjustments to training and oversight demonstrate a responsible approach to clinical development.
-
Broader Implications for Lymphatic Disorders: Beyond ADHF, the eLym system’s success could pave the way for further exploration of its therapeutic potential in other conditions characterized by lymphatic dysfunction and fluid accumulation. This could include various forms of edema, lymphedema, and other related disorders, opening up new avenues for research and treatment development in a range of medical fields.
The upcoming LYMPH-HF trial will be closely watched by the medical community, researchers, and patient advocacy groups. The successful validation of the eLym system could represent a significant leap forward in the fight against acute decompensated heart failure, offering a much-needed new hope for millions of patients worldwide. The journey ahead, while potentially challenging, is marked by the promise of a more effective and comprehensive approach to managing this debilitating condition.
About the Author
